Sweden · Delayed Price · Currency is SEK Swedish Orphan Biovitrum AB Earnings Call Transcripts
Fiscal Year 2026
-
Q2 saw 29% revenue growth and a 35% adjusted EBITA margin, driven by strong performance across all regions and key products like ALTUVOCT, Doptelet, and Gamifant. The outlook for 2026 was raised, with continued pipeline progress and new launches supporting long-term growth.
-
Q1 2026 saw 24% revenue growth and a 38% adjusted EBITDA margin, driven by strong launches and portfolio expansion. Key products like ALTUVOCT, Gamifant, Aspaveli, and Doptelet delivered robust growth, and the outlook for 2026 remains positive with continued investment in launches and R&D.
-
Ambitious plans target doubling revenue to SEK 55 billion by 2030, driven by six major product launches and global expansion. Robust R&D, digital innovation, and disciplined financial management underpin growth, with a focus on rare diseases and new therapeutic areas.
-
Strong Q3 growth and a strategic portfolio now drive 64% of business, with six major launches planned through 2028. The Arthrosi acquisition and promising pipeline advances, including Gamifant in sepsis, support optimism for sustained growth.
Fiscal Year 2025
-
Q4 and full-year 2025 saw robust revenue and margin growth, driven by strategic portfolio expansion and successful product launches. 2026 will be a transition year with significant investments moderating margins, but multiple high-value launches are expected to drive long-term growth.
-
The acquisition brings a late-stage, best-in-class gout therapy into the portfolio, targeting a large unmet need and supporting long-term growth. The deal is structured for financial flexibility, with expected accretion to sales and earnings from 2030 onward.
-
Q3 saw 21% revenue growth and a 47% adjusted EBITDA margin, driven by strong performance in strategic products and pipeline progress. Guidance for 2025 was upgraded, with continued growth expected and investments planned for key launches. Bonjour impairment impacted net earnings.
-
NASP, a novel monthly uricase therapy for uncontrolled gout, demonstrated significant efficacy and safety in Phase 3 trials, with rapid sUA reduction, high tophi resolution, and a favorable safety profile. Regulatory submission is accepted, targeting a U.S. launch in mid-2026, with robust commercialization and supply chain plans in place.
-
Q2 2025 saw 22% revenue growth and a 34% adjusted EBITDA margin, driven by strong launches and portfolio expansion. Key milestones included FDA approval for Gamifant in HLH MAS, a major royalty agreement with Apellis, and robust performance across hematology and immunology segments.
-
The phase III VALIANT study showed pegcetacoplan led to a 67% reduction in proteinuria and significant stabilization of kidney function at 52 weeks in C3G and ICMPGN patients, with strong safety and tolerability. Regulatory filings are progressing, with a European launch targeted for early 2026.
-
Q1 2025 saw 3% revenue growth and a 36% Adjusted EBITDA margin, with the strategic portfolio up 46%. ALTUVOCT's launch drove strong hematology results, while immunology and international markets also performed well. Guidance for high single-digit revenue growth and mid-30s EBITDA margin remains unchanged.
-
Strong 2024 performance was driven by rare disease therapies, with ALTUVOCT's rapid uptake in Germany and ongoing European expansion. Key pipeline milestones and regulatory decisions are expected in 2025, while launch preparations for Aspaveli in nephrology target a sizable patient population.
Fiscal Year 2024
-
Full-year revenue grew 19% to SEK 26 billion, with strong hematology and strategic portfolio expansion. 2025 guidance anticipates high single-digit revenue growth and mid-30s EBITDA margin, supported by new launches and robust pipeline progress.
-
Q3 2024 saw 39% revenue growth and a 43% adjusted EBITDA margin, driven by strong hematology and immunology sales, especially from Altuviiio and Beyfortus. Upgraded guidance anticipates mid-teens revenue growth for 2024, with continued R&D and launch investments.
-
The VALIANT phase III trial showed pegcetacoplan achieved a 68% reduction in proteinuria versus placebo in C3G and IC-MPGN, with consistent efficacy across subgroups and a favorable safety profile. Experts highlighted the unprecedented efficacy and expect rapid regulatory progress and strong market uptake.
-
Q2 2024 saw 11% revenue growth (26% ex-China Doptelet), strong EBITDA margin, and upgraded full-year guidance. Pipeline advances included Altuvoct approval and SEL-212 FDA filing, while Vonjo and other key products drove segment growth despite competitive headwinds.